Pheton Holdings Ltd. is a holding company incorporated in the Cayman Islands on Nov. 2, 2022. (Incorporated in the Cayman Islands)
We operate through our PRC operating entity in China, Beijing Feitian, which is a wholly owned subsidiary of Jinruixi, our wholly foreign-owned enterprise under the PRC law. As of the date of this prospectus, all of our business is conducted by Beijing Feitian.
Beijing Feitian is a healthcare solution provider dedicated to the development and commercialization of treatment software used for brachytherapy, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Beijing Feitian’s proprietary TPS product, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS stands for Feitian Treatment Planning Software.
FTTPS is an advanced and user-oriented software for treatment planning of a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect organs at risk (“OARs”) and produce a dose distribution plan for brachytherapy for cancer patients. Beijing Feitian’s operations include the sales of Medical Auxiliary Supplies, such as printed 3D molds, seed implant needles, computer workstations, etc., and the sales of FTTPS-related technical advisories or provisions of consulting services. However, as of the date of this prospectus, except for burning FTTPS onto CDs, Beijing Feitian does not engage in any other manufacturing activities itself. Instead, we procure other products we sell from third-party suppliers.
*Note: Net loss and revenue figures are for the 12 months that ended on June 30, 2023.
(Pheton Holdings Ltd. filed its F-1 on Oct. 11, 2023, and disclosed terms for its IPO: 2.5 million Class A ordinary shares at $4.00 to $5.00 to raise $11.25 million. Pheton submitted confidential IPO documents to the SEC on June 2, 2023.)